Life-Cycle Management Heads To Court; Abbott Faces Antitrust Trial On Tricor
Executive Summary
A Delaware federal court will decide whether innovator firms' strategy of making minor changes to a product late in patent life, thereby blocking generic competition, is anticompetitive
You may also be interested in...
Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
States Sue Abbott Over Its “Scheme” To Block Generic TriCor Competition
Eighteen states and the District of Columbia filed an antitrust suit against Abbott and its marketing partner Fournier claiming they illegally blocked generic competition for TriCor (fenofibrate) by making minor changes in the drug's formulation and filing baseless patent infringement suits
States Sue Abbott Over Its “Scheme” To Block Generic TriCor Competition
Eighteen states and the District of Columbia filed an antitrust suit against Abbott and its marketing partner Fournier claiming they illegally blocked generic competition for TriCor (fenofibrate) by making minor changes in the drug's formulation and filing baseless patent infringement suits